WO2016150337A1 - Ahu377的晶型及其制备方法与用途 - Google Patents

Ahu377的晶型及其制备方法与用途 Download PDF

Info

Publication number
WO2016150337A1
WO2016150337A1 PCT/CN2016/076660 CN2016076660W WO2016150337A1 WO 2016150337 A1 WO2016150337 A1 WO 2016150337A1 CN 2016076660 W CN2016076660 W CN 2016076660W WO 2016150337 A1 WO2016150337 A1 WO 2016150337A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
ahu377
heart failure
solid form
Prior art date
Application number
PCT/CN2016/076660
Other languages
English (en)
French (fr)
Inventor
陈敏华
张炎锋
杨朝惠
余姝
张晓宇
张良
Original Assignee
苏州晶云药物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56333431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016150337(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 苏州晶云药物科技有限公司 filed Critical 苏州晶云药物科技有限公司
Priority to US15/559,824 priority Critical patent/US10233144B2/en
Priority to MX2017012110A priority patent/MX2017012110A/es
Priority to EP16767714.5A priority patent/EP3272734A4/en
Priority to CA2980224A priority patent/CA2980224C/en
Priority to AU2016236659A priority patent/AU2016236659B9/en
Priority to JP2017566187A priority patent/JP2018509466A/ja
Publication of WO2016150337A1 publication Critical patent/WO2016150337A1/zh
Priority to IL254597A priority patent/IL254597A0/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to the field of chemical medicine, in particular to a crystal form of AHU377 and a preparation method and use thereof.
  • Patent US5354892A discloses for the first time the preparation of the AHU377 structure and its sodium salt; however, the AHU377 crystal form is not involved in this patent.
  • Patent CN102702119A discloses a dual-acting complex LCZ696 having the structural formula shown in formula (II).
  • the complex has AHU377 and valsartan as active ingredients, and the two active ingredients are connected by hydrogen bonding.
  • the patent also discloses a method for preparing LCZ696 using AHU377 or a salt thereof.
  • LCZ696 is clinically proven to be useful in the treatment of a variety of cardiovascular and/or renal diseases. In 2015, LCZ696 was marketed in the United States under the trade name "ENTRESTO".
  • AHU377 exists in the form of a thick substance at room temperature.
  • the transfer and quantification of the thick AHU377 raw material has insurmountable operational difficulties.
  • the prior art can only achieve the purpose of material transfer and accurate quantification by preparing AHU377 as a solid salt first, but the subsequent preparation of LCZ696 still needs to break the salt into AHU377 free acid.
  • the existing process is not only cumbersome to operate, but also introduces a large amount of impurity ions, which is not conducive to process quality control.
  • the technical problem to be solved by the present invention is to provide a solid form of AHU377 which can effectively solve the problems of the prior art.
  • the compound of formula I is in solid form.
  • the compounds of formula I are in crystalline form.
  • the solid form is in the form of an anhydrate, a hydrate or a solvate.
  • the solid form provided by the present invention is an anhydrate in crystalline form and is designated as Form I.
  • the crystal form provided by the invention has good stability and low wettability, and is suitable for industrial production.
  • the solid form is Form I
  • the X-ray powder diffraction pattern of Form I has characteristic peaks at 2theta values of 17.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, and 9.8° ⁇ 0.2°. .
  • the X-ray powder diffraction pattern of Form I has a characteristic peak at a 2theta value of 12.3 ° ⁇ 0.2 °, 8.2 ° ⁇ 0.2 °, 4.1 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form I also has a characteristic peak at 2theta values of 13.0 ° ⁇ 0.2 °, 18.4 ° ⁇ 0.2 °, 13.8 ° ⁇ 0.2 °, and 6.1 ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of the Form I is 17.2° ⁇ 0.2°, 16.4° ⁇ 0.2°, 9.8° ⁇ 0.2°, 12.3 ⁇ 0.2°, 8.2° ⁇ 0.2°, 4.1 in the 2theta value. Characteristic peaks are found at ° ⁇ 0.2°, 13.0° ⁇ 0.2°, 18.4° ⁇ 0.2°, 13.8° ⁇ 0.2°, and 6.1 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of Form I provided by the present invention is substantially identical to that of Figure 1.
  • the crystal form I provided by the present invention starts to have an endothermic peak when heated to around 72 ° C, and the differential scanning calorimetry chart is basically as shown in FIG. 2 .
  • the crystal form I provided by the present invention has a weight loss gradient of about 0.9% when heated to 140 ° C, and the thermogravimetric analysis chart is basically as shown in FIG. 3 .
  • the invention also provides a process for the preparation of the solid form of the compound of the formula I, wherein the solid form of the compound of the formula I is a condensate of the compound of the formula I in the form of an alcohol, an ether, a ketone or an aromatic hydrocarbon. Or a plurality of organic solvents are obtained by crystallization in a mixed system of an alkane or one or two solvents of water.
  • the mixing system is a mixture of toluene and n-heptane.
  • the viscous material of the compound of formula I is first dissolved in the toluene and then the n-heptane is added for crystallization to give the solid form of the compound of formula I.
  • the weight ratio of the added mass of the compound of the formula I to the added volume of toluene is from 0.1 to 0.2 g/mL.
  • the crystallization method comprises anti-solvent addition, volatilization, stirring or cooling crystallization.
  • the invention also provides the use of a solid form of the compound of formula I for the manufacture of a medicament for the treatment of anti-heart failure.
  • the present invention also provides an anti-heart failure drug, wherein the active ingredient of the anti-heart failure drug comprises a complex formed by the valsartan and the solid form of the compound of the formula I.
  • the present invention also provides a method for preparing the anti-heart failure medicament, wherein the solid form of the compound of the formula I and the valsartan and the sodium-containing alkaline substance are in a ketone solvent or a ketone solvent and water. The system reacts to obtain the anti-heart failure drug.
  • the ratio of the solid form of the compound of formula I to the valsartan is from 1.1:1 to 1:1.1.
  • the sodium ion-containing alkaline substance comprises sodium hydroxide.
  • the ketone solvent comprises acetone.
  • the water quality of the reaction system does not exceed 6%.
  • the AHU377 prepared by the prior art is a thick substance, and there is no patent or literature report on the crystal form of AHU377.
  • the inventors have studied and found a crystal form suitable for development.
  • the crystal form of AHU377 prepared by the invention has good stability, low wettability, strong impurity removal ability, obvious purification effect and strong economic value.
  • the AHU377 crystal form prepared by the invention can be used for the preparation of the anti-heart failure drug LCZ696.
  • the prior art overcomes the difficulty of transferring and accurately quantifying the AHU377 thick material, and simplifies the process flow and avoids the introduction of impurity ions, which is of great significance for the industrial production and quality control of the LCZ696.
  • Example 1 is an XRPD pattern of Form A of AHU377 prepared in Example 1;
  • Example 2 is a DSC chart of Form A of AHU377 prepared in Example 1;
  • Example 3 is a TGA diagram of Form A of AHU377 prepared in Example 1;
  • Example 4 is a DVS diagram of Form A of AHU377 prepared in Example 1;
  • Figure 5 is a PLM diagram of Form A of AHU377 prepared in Example 1;
  • Example 6 is a comparative diagram of the morphology of AHU377 crystal form I and the thick material prepared in Example 1, wherein the left side view is AHU377 crystal form I, which is white powder; the right side view is AHU377 thick substance, which is light yellow. , thick honey;
  • test methods described are generally carried out under conventional conditions or conditions recommended by the manufacturer.
  • the AHU377 starting material is a condensate prepared according to the prior art, and the preparation method thereof can be referred to US Pat. No. 5,354,892 A, and the other raw materials are all commercially available.
  • the X-ray powder diffraction pattern of the present invention was collected on a Panalytical Empyrean X-ray powder diffractometer at a temperature of room temperature (about 25 ° C).
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of the differential scanning calorimetry (DSC) described in the present invention are as follows:
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q5000.
  • the method parameters of the thermogravimetric analysis (TGA) described in the present invention are as follows:
  • the dynamic moisture adsorption (DVS) map of the present invention is by SMS Company (Surface Measurement) Collected on an Intrinsic Dynamic Moisture Absorber manufactured by Systems Ltd.).
  • the method parameters of the dynamic moisture adsorber are as follows:
  • Relative humidity range 0%RH-95%RH
  • AHU377 801.8 mg was dissolved in 5 mL of toluene solution, and 5 mL of n-heptane was added thereto, followed by stirring at 4 ° C overnight to obtain.
  • AHU377 (starting purity of 98.74%) was dissolved in 3 mL of toluene solution, and after dissolution, 3 mL of n-heptane was gradually added. During the process, AHU377 Form I was added as a seed crystal, and the mixture was stirred at room temperature (25 ° C). get. The final crystal form of AHU377 was 99.64% pure. The preparation of AHU377 crystal form I can play the role of purification of the drug substance. Through the HPLC purity test, it was found that the purity was increased from 98.74% to 99.64%, and the purification effect was remarkable.
  • AHU377 (starting purity of 98.74%) was dissolved in 20mL of toluene solution. After dissolving, 10mL of n-heptane was gradually added. During the process, AHU377 crystal form I was added as seed crystal and placed at room temperature. It can be obtained by stirring at (25 ° C). The final purity of AHU377 crystal form was 99.69%.
  • Example 1 of the present invention Approximately 10 mg of AHU377 Form I prepared in Example 1 of the present invention was tested for its wettability by a dynamic moisture adsorption (DVS) instrument. The experimental results are shown in Table 4. The wettability DVS pattern of Form I is shown in Figure 4.
  • the wetting weight gain is not less than 15%
  • Humidity Wet weight gain is less than 15% but not less than 2%
  • wetting gain is less than 2% but not less than 0.2%
  • wetting gain is less than 0.2%
  • the AHU377 crystal form I obtained in Example 1 of the present invention was subjected to a polarizing microscope photograph, as shown in FIG. From the results of the photographing by the polarizing microscope, the AHU377 crystal form I of the present invention has a needle shape and good dispersibility.
  • AHU377 crystal form I is white powder (as shown in the left figure of Fig. 6), which is convenient for sampling and quantification, while AHU377 is light yellow and thick. Thick honey (as shown in the right figure of Figure 6), when the temperature is low, the surface appears to be knotted, sampling and quantification is difficult.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及式(I)化合物的新晶型及其制备方法和用途。本发明提供的新晶型稳定性好，引湿性低，工艺提纯效果显著。本发明提供的式(I)化合物的新晶型可用于制备抗心衰药物的用途。

Description

AHU377的晶型及其制备方法与用途 技术领域
本发明涉及化学医药领域，特别是涉及AHU377的晶型及其制备方法与用途。
背景技术
AHU377，化学名称为(2R，4S)-5-联苯-4-基-4-(3-羧基-丙酰基氨基)-2-甲基-戊酸乙酯，其结构式如式(I)：
Figure PCTCN2016076660-appb-000001
专利US5354892A首次公开了AHU377结构及其钠盐的制备方法；但该专利中并未涉及AHU377晶型。
专利CN102702119A公开了一种双重作用的复合物LCZ696，结构式如式(II)所示。该复合物以AHU377和缬沙坦为活性成分，两种活性成分之间通过氢键连接。专利也公开了AHU377或其盐用于制备LCZ696的方法。LCZ696临床证实可用于治疗多种心血管和/或肾脏疾病，2015年LCZ696以商品名“ENTRESTO”在美国上市。
Figure PCTCN2016076660-appb-000002
发明人总结现有技术，发现室温下AHU377是以稠状物形式存在，在工业化生产LCZ696过程中，稠状物AHU377原料的转移和定量具有难以克服的操作困难。现有技术只能通过先将AHU377制备成固体盐来达成物料转移和精确定量的目的，但后续制备LCZ696仍需破盐成AHU377游离酸。现有工艺不但操作繁琐，也引入了大量杂质离子，不利于工艺质量控制。
基于现有技术的问题，寻找到AHU377的固体形式，便于LCZ696制备工艺中精确定量和转移、避免引人杂质离子以及简化工艺过程具有重要意义。
发明内容
本发明所要解决的技术问题是提供一种AHU377的固体形式，其能够有效解决现有技术存在的问题。
为解决上述技术问题，本发明采用如下技术方案：
式I化合物，
Figure PCTCN2016076660-appb-000003
Figure PCTCN2016076660-appb-000004
所述的式I化合物为固体形式。
具体地，所述的式I化合物为结晶形式。
具体地，所述的固体形式为无水物形式、水合物形式或溶剂合物形式。
本发明提供的固体形式为结晶形式的无水物，命名为晶型I。本发明提供的晶型稳定性良好，引湿性低，适合工业化生产。
具体地，所述的固体形式为晶型I，所述的晶型I的X射线粉末衍射图在2theta值为17.2°±0.2°、16.4°±0.2°、9.8°±0.2°处具有特征峰。
进一步优选地，所述的晶型I的X射线粉末衍射图还在2theta值为12.3°±0.2°、8.2°±0.2°、4.1°±0.2°处具有特征峰。
更优选地，所述的晶型I的X射线粉末衍射图还在2theta值为13.0°±0.2°、18.4°±0.2°、13.8°±0.2°、6.1±0.2°处具有特征峰。
具体地，所述的晶型I的X射线粉末衍射图在2theta值为17.2°±0.2°、16.4°±0.2°、9.8°±0.2°、12.3°±0.2°、8.2°±0.2°、4.1°±0.2°、13.0°±0.2°、18.4°±0.2°、13.8°±0.2°、6.1±0.2°处具有特征峰。
本发明提供的晶型I的X射线粉末衍射图基本上与图1一致。
本发明提供的晶型I，加热至72℃附近开始出现吸热峰，其差示扫描量热分析图基本如图2所示。
本发明提供的晶型I，加热至140℃时，具有约0.9％的重量损失梯度，其热重分析图基本如图3所示。
本发明还提供一种所述的式I化合物固体形式的制备方法，所述式I化合物的固体形式为式I化合物的稠状物在醇类、醚类、酮类、芳香烃类的一种或多种有机溶剂与烷烃类、水的一种或两种溶剂的混合体系中析晶得到。
优选地，所述的混合体系为甲苯和正庚烷的混合物。
进一步优选地，将式I化合物的稠状物先溶于所述的甲苯中，然后再加入所述的正庚烷，进行析晶得到所述的式I化合物的固体形式。
更为优选地，所述的式I化合物的稠状物的添加质量与所述的甲苯的添加体积比为0.1～0.2g/mL。
优选地，所述的析晶方法包括反溶剂添加、挥发、搅拌或降温结晶。
本发明还提供一种所述的式I化合物的固体形式在制备治疗抗心衰药物中的用途。
本发明还提供一种抗心衰药物，所述的抗心衰药物的活性成分包括缬沙坦和所述的式I化合物的固体形式形成的复合物。
本发明还提供一种所述的抗心衰药物的制备方法，使所述的式I化合物的固体形式和缬沙坦以及含钠离子的碱性物质在酮类溶剂或酮类溶剂和水的体系反应得到所述的抗心衰药物。
优选地，所述的式I化合物的固体形式与所述的缬沙坦的投料质量比为1.1∶1～1∶1.1。
优选地，所述的含钠离子的碱性物质包括氢氧化钠。
优选地，所述的酮类溶剂包括丙酮。
更进一步的，反应体系含水质量不超过6％。
本发明的有益效果为：
现有技术制备的AHU377均为稠状物，且尚无专利或文献报道AHU377的晶型，发明人经过研究，找到了适合开发的晶型。本发明制备的AHU377晶型稳定性好，引湿性较低，除杂能力强，提纯效果明显，具有很强的经济价值。
本发明制备的AHU377晶型可用于抗心衰药物LCZ696的制备。克服了现有技术中采用AHU377稠状物为起始物导致难以转移和精确定量的困难，也简化了工艺流程，避免了杂质离子引入，对于LCZ696的工业化生产和质量控制具有重大的意义。
附图说明
图1为实施例1制得的AHU377晶型I的XRPD图；
图2为实施例1制得的AHU377晶型I的DSC图；
图3为实施例1制得的AHU377晶型I的TGA图；
图4为实施例1制得的AHU377晶型I的DVS图；
图5为实施例1制得的AHU377晶型I的PLM图；
图6为实施例1制得的AHU377晶型I与稠状物的形态对比图，其中，左侧图为AHU377晶型I，呈白色粉末状；右侧图为AHU377稠状物，为浅黄色，呈浓稠的蜂蜜状；
图7为实施例6制备得到的LCZ696的XRPD图。
具体实施方式
以下将通过具体实施例进一步阐述本发明，但并不用于限制本发明的保护范围。本领域技术人员可在权利要求范围内对制备方法和使用仪器作出改进，这些改进也应视为本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
下述实施例中，所述的试验方法通常按照常规条件或制造厂商建议的条件实施。所述AHU377起始物为按照现有技术制备得到的稠状物，其制备方法可参考US5354892A，其余原料均通过市售得到。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
DVS：动态水分吸附
PLM：偏光显微镜
本发明所述的X射线粉末衍射图在Panalytical Empyrean X射线粉末衍射仪上采集，检测温度为室温(25℃左右)。本发明所述的X射线粉末衍射的方法参数如下：
X射线反射参数：Cu，Kα
Kα1
Figure PCTCN2016076660-appb-000005
1.540598；Kα2
Figure PCTCN2016076660-appb-000006
1.544426
Kα2/Kα1强度比例：0.50
电压：45仟伏特(kV)
电流：40毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的差示扫描量热分析(DSC)图在TA Q2000上采集。本发明所述的差示扫描量热分析(DSC)的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的热重分析(TGA)图在TA Q5000上采集。本发明所述的热重分析(TGA)的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述动态水分吸附(DVS)图在由SMS公司(Surface Measurement  Systems Ltd.)生产的Intrinsic动态水分吸附仪上采集。所述的动态水分吸附仪的方法参数如下：
温度：25℃
载气，流速：N2，200毫升/分钟
单位时间质量变化：0.002％/分钟
相对湿度范围：0％RH-95％RH
实施例1
AHU377晶型I的制备方法：
将801.8mg AHU377溶于5mL的甲苯溶液中，再加入5mL的正庚烷，然后放置于4℃条件下搅拌过夜，即可得到。
本实施例得到的晶型I的X射线粉末衍射数据如表1所示。其XRPD图如图1，其DSC图如图2，其TGA图如图3。
表1
2theta d间隔 强度％
4.09 21.63 37.77
4.34 20.38 25.44
5.07 17.44 16.66
5.44 16.26 25.99
6.11 14.46 26.56
6.39 13.82 23.70
6.89 12.83 13.96
8.15 10.84 40.06
8.58 10.30 18.80
9.83 9.00 52.19
10.17 8.70 9.34
10.89 8.12 7.89
12.31 7.19 41.81
13.00 6.81 33.85
13.82 6.41 30.86
14.27 6.21 20.37
15.25 5.81 9.01
16.36 5.42 71.29
17.24 5.14 100.00
17.82 4.98 18.96
18.42 4.82 33.68
19.05 4.66 14.82
19.25 4.61 16.49
19.60 4.53 19.15
20.24 4.39 17.56
20.47 4.34 19.84
20.82 4.27 18.95
21.52 4.13 23.00
21.93 4.05 8.30
22.28 3.99 9.61
22.55 3.94 18.26
22.84 3.89 10.60
23.25 3.83 8.86
23.60 3.77 11.13
24.31 3.66 10.10
24.73 3.60 7.97
26.03 3.42 7.84
27.49 3.24 4.04
27.86 3.20 4.20
28.78 3.10 2.65
29.81 3.00 3.44
30.27 2.95 4.40
30.84 2.90 1.85
31.99 2.80 3.81
32.67 2.74 1.72
33.10 2.71 1.36
33.65 2.66 2.95
34.10 2.63 1.06
34.72 2.58 3.24
35.66 2.52 1.87
实施例2
AHU377晶型I的制备方法：
将510mg AHU377(起始纯度为98.74％)溶于3mL甲苯溶液中，溶清后逐步加入3mL正庚烷，过程中加入AHU377晶型I作为晶种，放置室温(25℃)下搅拌，即可得到。最终得到的AHU377晶型纯度为99.64％。AHU377晶型I的制备能起到原料药提纯的作用。通过HPLC纯度测试，能够发现纯度由98.74％提升至99.64％，提纯效果显著。
本实施例得到的晶型的X射线粉末衍射数据如表2所示。
表2
2theta d间隔 强度％
4.09 21.62 32.91
4.33 20.41 29.77
5.43 16.28 29.01
6.11 14.46 19.82
6.39 13.83 28.42
6.87 12.87 10.47
8.18 10.81 26.73
8.58 10.30 14.88
9.87 8.97 40.46
12.32 7.18 37.11
13.01 6.80 44.62
13.85 6.40 31.80
14.21 6.23 20.05
15.22 5.82 9.19
16.40 5.40 62.77
17.27 5.14 100.00
17.83 4.98 20.31
18.45 4.81 19.96
19.24 4.61 17.64
19.63 4.52 12.80
20.26 4.38 10.28
20.81 4.27 19.68
21.48 4.14 23.13
22.58 3.94 12.92
22.85 3.89 8.70
23.23 3.83 9.03
23.63 3.77 8.94
24.36 3.65 7.34
24.76 3.60 7.34
25.92 3.44 5.87
27.88 3.20 3.90
29.12 3.07 3.04
30.28 2.95 5.03
36.32 2.47 2.19
37.71 2.39 3.21
实施例3
AHU377晶型I的制备方法：
将2.02gAHU377(起始纯度为98.74％)溶于20mL的甲苯溶液中，溶清后逐步加入10mL正庚烷，过程中加入AHU377晶型I作为晶种，放置室温 (25℃)下搅拌，即可得到。最终得到的AHU377晶型纯度为99.69％。
本实施例得到的晶型的X射线粉末衍射数据如表3所示。
表3
2theta d间隔 强度％
4.09 21.61 43.10
4.33 20.43 27.42
5.05 17.52 14.43
5.42 16.29 23.58
6.10 14.49 18.20
6.42 13.77 18.18
6.90 12.81 8.81
8.13 10.88 25.69
8.58 10.31 13.18
9.90 8.94 30.22
10.89 8.12 4.92
12.31 7.19 29.62
13.02 6.80 28.37
13.86 6.39 26.57
14.22 6.23 18.20
15.25 5.81 8.51
16.40 5.41 62.51
17.30 5.13 100.00
17.84 4.97 22.96
18.45 4.81 24.70
19.28 4.60 23.11
19.64 4.52 16.76
20.31 4.37 16.22
20.54 4.32 18.27
20.85 4.26 24.69
21.59 4.12 28.98
22.60 3.93 17.07
23.67 3.76 12.55
24.36 3.65 11.74
24.78 3.59 10.78
26.02 3.42 11.14
27.93 3.19 5.64
29.16 3.06 4.64
30.34 2.95 5.14
32.10 2.79 2.71
33.74 2.66 3.66
34.77 2.58 2.64
35.76 2.51 2.66
36.36 2.47 5.06
37.75 2.38 6.14
实施例4
AHU377晶型I用于制备LCZ696：
将10.1mg的AHU377晶型I与10.2mg的缬沙坦放置于玻璃小瓶中，再加入3.1mg NaOH，然后加1.0mL的丙酮溶液，放置于室温(25℃)下搅拌过夜，分离固体得到LCZ696。
实施例5
AHU377晶型I用于制备LCZ696：
将201.0mg的AHU377晶型I和213.4mg的缬沙坦溶于4mL的丙酮中，溶清后加入135μL的氢氧化钠水溶液(氢氧化钠∶水的质量比为1∶2)放在40℃下搅拌并加入LCZ696作为晶种，搅拌约3小时即可得到。
实施例6
AHU377晶型I用于制备LCZ696：
将202.2mg的AHU377晶型I和222.1mg的缬沙坦溶于4mL的丙酮中，室温(25℃)下溶清后逐步加入135μL的氢氧化钠水溶液(氢氧化钠∶水的质 量比为1∶2)，过程中加入LCZ696作为晶种，最后加入4mL的丙酮，室温(25℃)搅拌约2.5小时即可得到。最终得到的样品杂质含量仅为0.14％。
通过本发明实施例得到的LCZ696的X射线粉末衍射图如图7所示。
实施例7
AHU377晶型I的引湿性实验：
取本发明的实施例1制得的AHU377晶型I约10mg采用动态水分吸附(DVS)仪测试其引湿性。实验结果如表4所示。晶型I的引湿性DVS图如图4所示。
表4
晶型 80％相对湿度的增重
AHU377晶型I 0.35％
关于引湿性特征描述与引湿性增重的界定(中国药典2010年版附录XIX J药物引湿性试验指导原则，实验条件：25℃±1℃，80％相对湿度)：
潮解：吸收足量水分形成液体
极具引湿性：引湿增重不小于15％
有引湿性：引湿增重小于15％但不小于2％
略有引湿性：引湿增重小于2％但不小于0.2％
无或几乎无引湿性：引湿增重小于0.2％
结果表明，本发明的AHU377晶型I在80％湿度下平衡后增重0.35％，根据引湿性增重的界定标准，属于略有引湿性。
实施例8
AHU377晶型I与稠状物的形态对比：
将本发明实施例1得到的AHU377晶型I进行偏光显微镜拍摄，如图5所示。从偏光显微镜的拍摄结果看，本发明的AHU377晶型I呈针状，分散性好。
AHU377晶型I与稠状物的形态对比图如图6所示，AHU377晶型I呈白色粉末状(如图6左图)，取样及定量方便，而AHU377稠状物为浅黄色，呈浓稠的蜂蜜状(如图6右图)，温度较低时表面出现板结，取样和定量困难。

Claims (18)

  1. 式I化合物，
    Figure PCTCN2016076660-appb-100001
    其特征在于：所述的式I化合物为固体形式。
  2. 根据权利要求1所述的式I化合物，其特征在于：所述的式I化合物为结晶形式。
  3. 根据权利要求1所述的式I化合物，其特征在于：所述的式I化合物为无水物形式、水合物形式或溶剂合物形式。
  4. 根据权利要求1至3中任一项所述的式I化合物，其特征在于：所述的结晶形式为晶型I，所述的晶型I的X射线粉末衍射图在2theta值为17.2°±0.2°、16.4°±0.2°、9.8°±0.2°处具有特征峰。
  5. 根据权利要求4所述的式I化合物，其特征在于：所述的晶型I的X射线粉末衍射图还在2theta值为12.3°±0.2°、8.2°±0.2°、4.1°±0.2°处具有特征峰。
  6. 根据权利要求4所述的式I化合物，其特征在于：所述的晶型I的X射线粉末衍射图还在2theta值为13.0°±0.2°、18.4°±0.2°、13.8°±0.2°、6.1±0.2°处具有特征峰。
  7. 根据权利要求1至3中任一项所述的式I化合物，其特征在于：所述的晶型I的X射线粉末衍射图在2theta值为17.2°±0.2°、16.4°±0.2°、9.8°±0.2°、 12.3°±0.2°、8.2°±0.2°、4.1°±0.2°、13.0°±0.2°、18.4°±0.2°、13.8°±0.2°、6.1±0.2°处具有特征峰。
  8. 一种如权利要求1至7中任一项所述的式I化合物固体形式的制备方法，其特征在于：所述式I化合物的固体形式为式I化合物的稠状物在醇类、醚类、酮类、芳香烃类的一种或多种有机溶剂与烷烃类、水的一种或两种溶剂的混合体系中析晶得到。
  9. 根据权利要求8所述的制备方法，其特征在于：所述的混合体系为甲苯和正庚烷的混合物。
  10. 根据权利要求9所述的制备方法，其特征在于：将式I化合物的稠状物先溶于所述的甲苯中，然后再加入所述的正庚烷，进行析晶得到所述的式I化合物的固体形式。
  11. 根据权利要求10所述的制备方法，其特征在于：所述的式I化合物的稠状物的添加质量与所述的甲苯的添加体积比为0.1～0.2g/mL。
  12. 根据权利要求8所述的制备方法，其特征在于：所述的析晶方法包括反溶剂添加、挥发、搅拌或降温结晶。
  13. 一种如权利要求1至7中任一项所述的式I化合物的固体形式在制备治疗抗心衰药物中的用途。
  14. 一种抗心衰药物，其特征在于：所述的抗心衰药物的活性成分包括缬沙坦和权利要求1至7中任一项所述的式I化合物的固体形式形成的复合物。
  15. 一种如权利要求14所述的抗心衰药物的制备方法，其特征在于：使所述的式I化合物的固体形式和缬沙坦以及含钠离子的碱性物质在酮类溶 剂或酮类溶剂和水的体系中反应得到所述的抗心衰药物。
  16. 根据权利要求15所述的抗心衰药物的制备方法，其特征在于：所述的式I化合物的固体形式与所述的缬沙坦的投料质量比为1.1∶1～1∶1.1。
  17. 根据权利要求15所述的抗心衰药物的制备方法，其特征在于：所述的含钠离子的碱性物质包括氢氧化钠。
  18. 根据权利要求15所述的抗心衰药物的制备方法，其特征在于：所述的酮类溶剂包括丙酮。
PCT/CN2016/076660 2015-03-20 2016-03-18 Ahu377的晶型及其制备方法与用途 WO2016150337A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US15/559,824 US10233144B2 (en) 2015-03-20 2016-03-18 Crystalline form of AHU377, preparation method and use thereof
MX2017012110A MX2017012110A (es) 2015-03-20 2016-03-18 Forma cristalina de ahu377, metodo de preparacion y uso de la misma.
EP16767714.5A EP3272734A4 (en) 2015-03-20 2016-03-18 Ahu377 crystal form, preparation method and use thereof
CA2980224A CA2980224C (en) 2015-03-20 2016-03-18 Crystalline form of ahu377, preparation method and use thereof
AU2016236659A AU2016236659B9 (en) 2015-03-20 2016-03-18 AHU377 crystal form, preparation method and use thereof
JP2017566187A JP2018509466A (ja) 2015-03-20 2016-03-18 Ａｈｕ３７７の結晶形、その製造方法及び用途
IL254597A IL254597A0 (en) 2015-03-20 2017-09-19 Crystalline form of ahu377, method for its preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510124555 2015-03-20
CN201510124555.1 2015-03-20

Publications (1)

Publication Number Publication Date
WO2016150337A1 true WO2016150337A1 (zh) 2016-09-29

Family

ID=56333431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/076660 WO2016150337A1 (zh) 2015-03-20 2016-03-18 Ahu377的晶型及其制备方法与用途

Country Status (9)

Country Link
US (1) US10233144B2 (zh)
EP (1) EP3272734A4 (zh)
JP (1) JP2018509466A (zh)
CN (1) CN105753732B (zh)
AU (1) AU2016236659B9 (zh)
CA (1) CA2980224C (zh)
IL (1) IL254597A0 (zh)
MX (1) MX2017012110A (zh)
WO (1) WO2016150337A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689A (zh) * 2005-11-09 2008-01-02 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN104230865A (zh) * 2013-06-13 2014-12-24 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途
CN104557600A (zh) * 2015-01-26 2015-04-29 苏州明锐医药科技有限公司 沙库比曲的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
CN106458857A (zh) * 2014-08-27 2017-02-22 上海翰森生物医药科技有限公司 AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016135751A1 (en) * 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689A (zh) * 2005-11-09 2008-01-02 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN104230865A (zh) * 2013-06-13 2014-12-24 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途
CN104557600A (zh) * 2015-01-26 2015-04-29 苏州明锐医药科技有限公司 沙库比曲的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3272734A4 *

Also Published As

Publication number Publication date
US20180086695A1 (en) 2018-03-29
JP2018509466A (ja) 2018-04-05
IL254597A0 (en) 2017-11-30
EP3272734A8 (en) 2018-04-11
CA2980224A1 (en) 2016-09-29
AU2016236659B9 (en) 2019-05-02
CN105753732B (zh) 2018-05-08
CN105753732A (zh) 2016-07-13
AU2016236659A1 (en) 2017-11-09
EP3272734A1 (en) 2018-01-24
EP3272734A4 (en) 2018-11-21
AU2016236659B2 (en) 2019-04-18
MX2017012110A (es) 2018-02-19
US10233144B2 (en) 2019-03-19
CA2980224C (en) 2019-06-25

Similar Documents

Publication Publication Date Title
US11111223B2 (en) Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
JP2021504297A (ja) Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態
WO2018050091A1 (zh) 奥扎莫德盐酸盐的晶型及其制备方法
WO2016124149A1 (zh) 一种治疗前列腺癌的抗雄激素类药物的新晶型及其制备方法
WO2017107972A1 (zh) 一种选择性s1p1受体激动剂的新晶型及其制备方法
CN110922403A (zh) 阿哌沙班与羧酸形成的共晶及其制备方法
WO2016150349A1 (zh) 一种pci-32765晶型a的制备方法
WO2021129589A1 (zh) Kd-025的新晶型及其制备方法
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
WO2016058472A1 (zh) 维生素d2与d3的共晶及其制备方法和用途
JP2021518403A (ja) 化合物の結晶形態及び化合物の結晶形態を生成する方法
WO2016127844A1 (zh) IPI-145的晶型α及其制备方法
WO2016150337A1 (zh) Ahu377的晶型及其制备方法与用途
WO2017177781A1 (zh) Ahu377的晶型及其制备方法与用途
WO2016119742A1 (zh) (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
CN109734580A (zh) 曲前列尼尔钠盐新晶型及制备方法
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
WO2012010092A1 (zh) 一种肽类物质的晶体及其制备方法和用途
WO2012013118A1 (zh) 硫酸卡维地洛的结晶、其制备方法及其在医药上的应用
US9834540B2 (en) Omeprazole Sodium semihydrate and preparation method thereof
WO2018001335A1 (zh) Nbi-98854的晶型及其制备方法和用途
CN109369713A (zh) 一种精草铵膦酸水合物晶体及其制备方法
WO2019057165A1 (zh) 盐酸伊达比星一水合物的晶型
WO2017152858A1 (zh) 色瑞替尼的晶型及其制备方法
WO2017032281A1 (zh) 帕比司他乳酸盐的新晶型

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16767714

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017566187

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2980224

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15559824

Country of ref document: US

Ref document number: 254597

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/012110

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2016767714

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016236659

Country of ref document: AU

Date of ref document: 20160318

Kind code of ref document: A